Extensive Circumferential Partial Thickness Sclerectomy in Nanophthalmic Eyes
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03748732 |
|
Recruitment Status : Unknown
Verified November 2018 by Ahmad Mansour, MD, Clinical Professor, AUB, Rafic Hariri University Hospital.
Recruitment status was: Active, not recruiting
First Posted : November 21, 2018
Last Update Posted : November 21, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Purpose: To describe an extensive scleral excision technique to treat or prevent uveal effusion in nanophthalmic eyes.
Design: Prospective interventional case series.
Methods:
- Setting: Institutional.
- Patient Population: Consecutive patients with nanophthalmos were operated on by one surgeon.
- Intervention Procedure: A single, 90% thickness scleral window extending from immediately behind the extraocular muscle insertions to the vortex veins was performed for 3 and 1/4 quadrants as a circumferential strip.
- Main Outcome Measure: Resolution or prevention of uveal effusion.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Nanophthalmos | Procedure: sclerectomy | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 30 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | surgery |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Extensive Circumferential Partial Thickness Sclerectomy in Nanophthalmic Eyes |
| Actual Study Start Date : | January 1, 2011 |
| Estimated Primary Completion Date : | January 1, 2020 |
| Estimated Study Completion Date : | January 1, 2020 |
- Procedure: sclerectomy
scleral flapOther Name: maximal scleral excision
- resolution of uveal effusion [ Time Frame: 1 month ]disappearence of uveal effusion by OCT
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: nanophthalmos -
Exclusion Criteria: None
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748732
| Lebanon | |
| Rafic Hariri University Hospital | |
| Beirut, South Beirut, Lebanon, 1136044 | |
| Study Chair: | Ahmad Mansour, MD | Rafic Hariri University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Ahmad Mansour, MD, Clinical Professor, AUB, Professor, Rafic Hariri University Hospital |
| ClinicalTrials.gov Identifier: | NCT03748732 |
| Other Study ID Numbers: |
RaficHaririUHAMM |
| First Posted: | November 21, 2018 Key Record Dates |
| Last Update Posted: | November 21, 2018 |
| Last Verified: | November 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | if part of collaboration, we will share the data |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
uveal effusion |
|
Microphthalmos Eye Abnormalities Eye Diseases Congenital Abnormalities |

